NIH PAR · NIDA · DP1
PAR-27-026: Avant Garde/Avenir Awards for Investigators Conducting High Risk/High Reward Research on HIV and Substance Use (or Substance Use Disorders) (DP1 Clinical Trial Optional)
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
The purpose of this notice of funding opportunity (NOFO) is to support innovative basic, clinical, translational, and implementation science research relevant to HIV and substance use. This initiative encourages high risk high impact transformative studies that advance knowledge and strategies for HIV prevention, diagnosis, treatment and virus suppression in people who use substances and/or have a substance use disorder.
- NOFO number
- PAR-27-026
- Type
- PAR
- Activity code
- DP1
- Primary institute
- NIDA · National Institute on Drug Abuse
- Clinical trials
- Optional
- Posted
- Jun 9, 2026
- Opens
- Aug 25, 2026
- Expires
- Sep 26, 2028
PAR-27-026 due dates
2 application due dates remain before the NOFO expires. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.
| New | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
|---|---|---|---|---|---|
| September 25, 2026 * | Not Applicable | Not Applicable | March 2027 | May 2027 | July 2027 |
| September 25, 2027 * | Not Applicable | Not Applicable | March 2028 | May 2028 | July 2028 |
| September 25, 2028 * | Not Applicable | Not Applicable | March 2029 | May 2029 | July 2029 |
What its predecessor PAR-23-125 funded
PAR-27-026 reissues PAR-23-125. Until awards appear under the new number, its funding history is the best guide to who wins under this program: 7 projects and $16.6M in FY2022–FY2026.
Projects funded
7
Distinct projects, FY2022–FY2026
New awards
7
Type 1 (new project) award records
NIH funding
$16.6M
Award dollars under PAR-23-125, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 1 | 1 | $2.5M |
| FY2025 | 3 | 3 | $7.0M |
| FY2026 | 3 | 3 | $7.1M |
Institutions with the most funding
- University of California, San Francisco$4.9M · 2 projects
- University of Washington$4.7M · 2 projects
- Boston Medical Center$2.7M · 1 project
- University of California Los Angeles$2.4M · 1 project
- Florida State University$2.0M · 1 project
Funding institutes
- NIDA$16.6M · 7
Activity codes funded
- DP27 records
Most recent new awards
- Development and Testing of a Mechanism-Driven Dialectical Behavior Therapy (DBT) Skills Coaching Powered by Generative AI: A Just-in-Time Adaptive Intervention to Reduce HIV and Substance Use Risks (opens NIH RePORTER)
Florida State University · 1DP2DA066204-01 · NIDA · Notice Jul 24, 2026
$2.0MDP2
- Psilocybin Therapy for Methamphetamine Use Disorder and HIV (opens NIH RePORTER)
University of California, San Francisco · 1DP2DA066200-01 · NIDA · Notice Jul 10, 2026
$2.5MDP2
- The LINK Intervention: Using informatics and implementation science to reduce missed opportunities to prevent opioid overdose and HIV infection (opens NIH RePORTER)
Boston Medical Center · 1DP2DA066177-01 · NIDA · Notice May 5, 2026
$2.7MDP2
- Enhancing Access to Timely Research to Prevent HIV Transmission and Effectively Treat Substance Use (opens NIH RePORTER)
University of California Los Angeles · 1DP2DA063114-01 · NIDA · Notice Jun 23, 2025
$2.4MDP2
- Community-Based Opioid Treatment (CBOT): Development and testing of a novel nurse-led model to deliver opioid use disorder treatment and HIV prevention and care in the community setting. (opens NIH RePORTER)
University of Washington · 1DP2DA063123-01 · NIDA · Notice Jun 13, 2025
$2.3MDP2
- Transforming systems of care to address HIV, HIV risk, and substance use disorders in prisons (opens NIH RePORTER)
University of Washington · 1DP2DA063100-01 · NIDA · Notice Jun 2, 2025
$2.3MDP2
FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.
Participating institutes
2 NIH institutes and offices take applications under PAR-27-026. Contact the program officer at the institute that fits your research before applying.
- NIDA · National Institute on Drug Abuse
- none
Related notices
NIH lists no related notices for PAR-27-026 yet.
Notices of Special Interest (NOSIs)
NIH has attached 1 NOSI to PAR-27-026; 1 are active. A NOSI flags a topic an institute wants to fund through this NOFO.
Award terms
- Application types allowed
- New The OER Glossary and the How to Apply - Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
- Award budget
- Application budgets are limited to 700,000 in total costs per year for established investigators. For early stage investigators ESIs) application budgets are limited to 375,000/year in total costs.
- Project period
- The maximum project period allowed is 5 years. NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.
- Funds available and number of awards
- The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.
Related NOFOs
- Reissue of PAR-23-125.
About this page
GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.